Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin Dose-Ranging Study in IBS-D
NCT00269412Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Dec 2005
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rifaximin in Irritable bowel syndrome with diarrhea (IBS-D) (5 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Adequate relief from Diarrhea-associated IBS (DIBS) symptoms at 2 weeks. Started Dec 2005; status: completed.
02
Drugs
rifaximin
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT00269412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269412.